$11.78
▲ +0.0% Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
FMC: Lowering target price to $9.00
FMC Files First Global Regulatory Submission With EPA for Rimisoxafen
FMC Files First Global Regulatory Submission for Rimisoxafen to US EPA
Overview
52-week range
$11
$45
1% of range
Avg surprise (last 2)
+71.0%
Avg reaction (last 1)
+0.4%
100% positive
Latest IV / EM
79%
EM ±18.0% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-2.25 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-4.52 | — | — | — | — | financials |
| Wed Jul 30, 2025 | Jun/2025 | $0.69 | $0.59 | +16.9% | — | — | earnings |
| Wed Apr 30, 2025 | Mar/2025 | $0.18 | $0.08 | +125.0% | — | +0.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.52 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $2.35 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.02 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.03 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.24 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Jul 29, 2026 | Jun/2026 | AMC | $0.21 | $0.69 | -69.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $247M | — | $129M | $406M | $317M | — | $386M | $398M |
| Operating income | $-81M | — | $-396M | $126M | $58M | — | $136M | $62M |
| Net income | $-281M | — | $-569M | $67M | $-16M | — | $65M | $295M |
| EPS (diluted) | $-2.25 | — | $-4.52 | $0.53 | $-0.12 | — | $0.52 | $2.35 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $391M | $584M | $498M | $438M | $315M | $357M | $417M | $472M |
| Inventory | $1.24B | $1.22B | $1.38B | $1.40B | $1.37B | $1.20B | $1.39B | $1.44B |
| Total current assets | $4.90B | $4.96B | $5.57B | $5.47B | $5.08B | $4.96B | $5.32B | $5.21B |
| Total assets | $9.42B | $9.69B | $12.08B | $12.30B | $11.80B | $11.65B | $12.22B | $12.13B |
| Long-term debt | $2.77B | $2.77B | $3.27B | $3.27B | $3.03B | $3.03B | $3.03B | $3.03B |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $1.82B | $2.07B | $3.77B | $4.40B | $4.38B | $4.49B | $4.61B | $4.56B |